Cancer cells down-regulate different genes to give them a selective advantage in invasiveness and/or metastasis. The SLC25A26 gene encodes the mitochondrial carrier that catalyzes the import of S-adenosylmethionine (SAM) into the mitochondrial matrix, required for mitochondrial methylation processes, and is down-regulated in cervical cancer cells. In this study we show that SLC25A26 is down-regulated due to gene promoter hypermethylation, as a mechanism to promote cell survival and proliferation. Furthermore, overexpression of SLC25A26 in CaSki cells increases mitochondrial SAM availability and promotes hypermethylation of mitochondrial DNA, leading to decreased expression of key respiratory complex subunits, reduction of mitochondrial ATP and release of cytochrome c. In addition, increased SAM transport into mitochondria leads to impairment of the methionine cycle with accumulation of homocysteine at the expense of glutathione, which is strongly reduced. All these events concur to arrest the cell cycle in the S phase, induce apoptosis and enhance chemosensitivity of SAM carrier-overexpressing CaSki cells to cisplatin.
Introduction
S-Adenosylmethionine (SAM) is the methyl donor fundamental for sustained epigenetic modifications, such as DNA methylation, and has been implicated in the pathogenesis underlying cancer development [1] .
Abnormal DNA methylation patterns related to persistent infection of human papilloma virus (HPV) represent an early and frequent alteration in cervical carcinogenesis [2] . Indeed, several genes, such as those for p16, death-associated protein kinase, tissue inhibitor of metalloproteinases-3 [3] , E-cadherin [4, 5] , cell adhesion molecule 1 and T-cell differentiation protein [6, 7] , are down-regulated through DNA methylation, contributing to the development, progression and/or metastasis of cervical cancer. Identification of new gene targets of epigenetic regulation might be useful to shed light on the biological processes and the molecular basis of the development of cervical cancer. SLC25A26 is the gene encoding S-adenosylmethionine carrier (SAMC), a member of the mitochondrial carrier family, a group of transport proteins that are found in the inner membrane of mitochondria [8, 9] . The physiological role of SAMC is to catalyze the uptake of SAM, the universal methyl donor, from cytosol into mitochondria, where it is required for the methylation of DNA, RNA and proteins, and as an intermediate in the biosynthesis of lipoic acid and ubiquinone [10] . SAM is produced in the cytosol by the methionine cycle pathway, through the transfer of adenosine from ATP to methionine catalyzed by methionine adenosyltrasferase [11] . SAM transport into mitochondria strictly depends on its synthesis, which is known to be regulated by both cytosolic and mitochondrial metabolism [12] . Mitochondrial metabolism regulates production of SAM through synthesis of ATP and folate, the folate cycle reactions being duplicated in the cytosol and mitochondria. Furthermore, the methionine cycle is strictly related to the transsulfuration pathway, with homocysteine being the linking metabolite between synthesis of methionine and cysteine. Since cystathionine b-synthase (CBS), the enzyme producing cystathionine from homocysteine, is allosterically activated by SAM [13] , glutathione production from cysteine is strictly related to the concentration of cytosolic SAM, which depends on the amount produced in the cytosol and withdrawn into the mitochondria. Similarly, availability of SAM to mitochondria might strongly modify the function of the mitochondrial targets of methylation. Mitochondrial DNA (mtDNA) is one of these targets. Methylation is known to modify mtDNA [14] , leading to altered expression of mtDNA-encoded genes in normal and pathological conditions [15] [16] [17] . We have shown that methyl metabolism and SAM availability significantly influence the amount of mtDNA being methylated, suggesting that the flux through methyl metabolism and mitochondrial function might be tightly linked and reciprocally regulated [15] . Furthermore, Bellizzi et al. [18] have highlighted the importance of methylation of the regulatory region D-loop in regulating the expression of some mtDNA-encoded proteins (i.e. respiratory complex subunits) and tRNAs or ribosomal RNA, leading to altered mitochondrial functionality. Based on this evidence, the levels of SLC25A26 expression are destined to have a strong impact on cell function by orchestrating several metabolic events. However, the conditions and the mechanisms by which SLC25A26 expression is modulated are still elusive. Due to its relationship with the methyl metabolism, we hypothesized that SLC25A26 could be a target gene for epigenetic modification in cervical cancer cells and this could have important consequences at both cellular and mitochondrial levels.
In this work we show for the first time that SLC25A26 is down-regulated by an epigenetic mechanism in CaSki and HeLa cells, and we have investigated the biochemical and functional significance of its repression by evaluating the effects of its up-regulation on mtDNA methylation, mitochondrial oxidative phosphorylation, the methionine cycle and cell viability. This work also highlights the importance of mtDNA epigenetics and the complex metabolic and epigenetic mechanisms related to mtDNA methylation in regulating mitochondrial and cellular functions.
Results

SLC25A26 gene is down-regulated in CaSki cells by promoter hypermethylation
Both cervical cancer cell lines CaSki and HeLa display a significant down-regulation of SLC25A26 (Fig. 1A) . Since DNA methylation is an early and frequent molecular alteration in cervical carcinogenesis with high-risk HPV [2] , we performed an in silico analysis of the SLC25A26 promoter gene and identified a CpG island from -370 to -5 bp containing 30 CpG sites. This region was subjected to quantitative bisulfite sequencing analysis using genomic DNA extracted from normal liver tissue, a non-tumoral cell line (HEK293), HeLa cells and CaSki cells. No methylated sites were found in non-tumoral DNA, whereas 13 and 15 methylated sites were found in CaSki and HeLa cells, respectively (Fig. 1B) .
To confirm that SLC25A26 expression was epigenetically regulated, we performed further investigation on CaSki cells that were treated with the methyltransferase inhibitor 5-aza-2 0 -deoxycytidine (5-Aza), for 48 and 72 h. Subsequent DNA methylation analysis by bisulfite-sequencing revealed a reduction of methylated sites after 48 h incubation time with 5-Aza and the disappearance of methylated sites after 72 h of incubation (Fig. 1C) . Consistently, SLC25A26 mRNA (Fig. 1C ) and protein levels (Fig. 1D) gradually increased as the 5-Aza incubation time was raised (from 48 to 72 h) with respect to untreated CaSki cells. To further confirm the methylation of SLC25A26 promoter, we tested the ability of methyl CpG binding protein 2 (MeCP2), a global transcriptional repressor, to bind methylated DNA. It is known that this protein binds only to methylated DNA leading to gene silencing, especially in cancer [19] . CaSki cells were treated with 10 lM 5-Aza for 48, 60 and 72 h, and then a chromatin immunoprecipitation (ChIP) experiment was performed on cellular lysates using a specific MeCP2 antibody. A reduction of MeCP2 binding was evident at 48 h and much more so at 60 h. No binding of MeCP2 was observed at 72 h (Fig. 1E) .
These results clearly show that promoter hypermethylation is the main cause of SLC25A26 down-regulation in CaSki cells as compared with untreated cells.
SLC25A26 overexpression affects the mtDNA methylation status in CaSki cells
Based on the observation of reduced SLC25A26 expression in cervical cancer cells, we employed a re- 2) (http://genome.imb-jena.de/ methtools). Bisulfite-generated sequences were compared among them and reported on a basepair scale. White and black circles indicate unmethylated and methylated cytosine at CpG sites, respectively. (C) SLC25A26 mRNA levels were quantified by real-time PCR of three independent RNA samples from CaSki cells after treatment with 5-Aza for 48 and 72 h. *P < 0.05, **P < 0.01, versus control (one-way ANOVA). (D) SLC25A26 protein expression was determined by western blot on lysates from CaSki cells after treatment with 5-Aza for 48 and 72 h. A representative of four blots is shown. (E) Chromatin of CaSki cells was immunoprecipitated by anti-MeCP2 antibody. PCR was performed using forward and reverse primers encompassing the SLC25A26 gene promoter from À302 to À7 bp. Lane 1, PCR of input DNA dilutions (1/10); lane 2 (No-Ab), PCR of the precipitates without antibody. expression system to investigate the requirement of low SAMC expression for cancer cell proliferation focusing on mitochondrial functionality. To this aim we transfected CaSki cells with a pcDNA3-SAMC construct containing the SLC25A26 cDNA (a reexpression system) or with the empty vector (as control). First of all we checked the expression level of SAMC in the transfected CaSki cells (Fig. 2A) . Then we evaluated the mitochondrial SAM content by mass spectrometry. As shown in Fig. 2B , the mitochondrial SAM levels were about 50% higher in SAMC-overexpressing CaSki cells than in control cells, suggesting that higher mitochondrial availability of SAM might affect the extent of mtDNA methylation. Next the levels of mtDNA methylation in pcDNA3-SAMC compared with control cells were measured. Notably, the purity of mtDNA was checked with different approaches (see 'Experimental procedures' and Fig. 2C-F) . SAMC overexpression led to a 20% increase in mtDNA methylation at 48 h after transfection and reached about 70% increase after 72 h as compared with mtDNA extracted from control CaSki cells (Fig. 2G) .
Subsequently the methylation status of the D-loop, the region that controls transcription of mtDNA, was determined. After extraction from control and 48 h/ 72 h SAMC-overexpressing CaSki cells, mtDNA was bisulfite-modified and used to amplify a portion of Dloop that was subjected to sequencing analysis. After 48 h of transfection all analyzed clones showed identical methylation patterns, with the presence of 11 methylated CpG cytosines in pcDNA3-SAMC transfected CaSki cells, whereas control cells (empty vector) contained only four methylated CpG sites (Fig. 2H) . Of note no cytosine outside CpGs was found to be methylated. The percentage of methylated CpG sites was about 40% higher in SAMC-overexpressing compared with control CaSki cells. Surprisingly, after 72 h of transfection the methylation pattern of all analyzed clones was different with only four methylation sites located at CpG sites and all the rest at cytosines outside the CpGs (Fig. 2I) . Thus, at 72 h the percentage of methylated cytosines at CpG sites was about 22% higher in SAMC-overexpressing compared with control cells, in which no methylation at both CpG and non-CpG sites was found. The total methylated levels (CpG + non-CpG) in SAMC-overexpressing CaSki cells increased about 100% at 72 h compared with 48 h of transfection. Interestingly, longer exposure to SAMC transfection introduced new mutations in the D-loop of CaSki cells (data not shown) suggesting that a progressive and severe damage of cell functions was underway.
These results clearly indicate that mtDNA and in particular the D-loop control region is hypermethylated due to SAMC overexpression and higher SAM mitochondrial levels.
SLC25A26 overexpression impairs mitochondrial oxidative phosphorylation
To evaluate the consequences of the mtDNA hypermethylation, the expression levels of complex I subunit ND6, a protein under D-loop expression control [20] , were determined. As shown in Fig. 3A , the amount of ND6 was reduced after 48 h of transfection with pcDNA3-SAMC and even more after 72 h as compared with control CaSki cells. This trend was shared by ND2 and cytochrome b (Cytb) but not by ND1, the expression of which was unaffected by SAMC overexpression (Fig. 3A) . ND6, ND2 and Cytb reduction was not due to a decrease in the mtDNA copy number as a consequence of apoptosis (see below). Indeed, the mtDNA/nuclear DNA ratio was unchanged at 48 h with respect to control cells but increased at 72 h ( Fig. 3B ), probably due to nuclear DNA degradation [21, 22] . The depletion of complex I subunits was confirmed by evaluating the mitochondrial and cytosolic ATP levels by mass spectrometry.
Mitochondrial ATP content was reduced by about 50% as compared with control cells indicating that oxidative phosphorylation is impaired in SAMC-overexpressing CaSki cells compared with control cells (Fig. 3C ). On the contrary, the cytosolic ATP levels were unchanged following SLC25A26 overexpression ( Fig. 3C ) suggesting that glycolytic ATP production is unaffected. In line with these findings, a gradual increase of intracellular and extracellular reactive oxygen species (ROS) levels was observed in SAMC-overexpressing CaSki cells after 48 and 72 h of transfection with respect to control cells ( Fig. 3D,E) . Therefore, the oxidative phosphorylation impairment caused by TaKaRa protocol ). The mtDNA genes ND1 and ND5 were used to represent mtDNA copy number. The values for the controls were set to 1. Data are expressed as means AE SD of three duplicate independent experiments. **P < 0.01 (one-way ANOVA). (C) ATP was measured in the mitochondria (left) and post-mitochondrial supernatant (right) of control and SAMC-overexpressing CaSki cells with mass spectrometry analysis. ATP levels are reported as means AE SD of at least four independent experiments. The significance of the difference between the mitochondrial ATP levels in SAMC overexpressing compared with control cells is indicated (*P < 0.05, one-way ANOVA). (D,E) Intracellular (D) and extracellular levels (E) of reactive oxygen species (ROS) determined by dichlorodihydrofluorescein and lucigenin after cell transfection with pcDNA3-SAMC for 48 or 72 h. Results are presented as means AE SD from three independent experiments. *P < 0.05, **P < 0.01 versus control (one-way ANOVA).
reduction of ND6, ND2 and Cytb expression is associated with oxidative stress, which may contribute to cell injury.
All together, these results point to a bioenergetic functional failure of the mitochondria in SAMC-overexpressing CaSki cells.
SLC25A26 overexpression reprograms the methionine cycle leading to reduced glutathione level
Since SAM is produced in the cytosol during the conversion of methionine to homocysteine, we questioned 
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The FEBS Journal 284 (2017) 967-984 ª 2017 Federation of European Biochemical Societies whether increased mitochondrial uptake of SAM (Fig. 2B) can affect the availability of the methyl cycle intermediates. CaSki cells transfected with pcDNA3-SAMC displayed an increase in homocysteine of about 50% (Fig. 4A) , a decrease in methionine of about 70% (Fig. 4B ) and a decrease in cysteine of about 80% (Fig. 4C) . This result correlated with a pronounced reduction expression of CBS, the enzyme responsible for the homocysteine to cystathionine conversion (Fig. 4D) . Cytosolic SAM was unchanged (not shown). These data indicate that the methionine cycle is strongly modified by SAMC overexpression. Since the remethylation and transsulfuration pathways are linked by homocysteine, we also evaluated the levels of glutathione, the important non-enzymatic component of the antioxidant defense. As shown in Fig. 4E -G, the levels of both oxidized glutathione (GSSG) and reduced glutathione (GSH) were lower in SAMC-overexpressing CaSki cells compared with control cells, suggesting that the intracellular antioxidant defense of cervical cancer cells is greatly impaired by SAMC overexpression.
SLC25A26 overexpression inhibits cervical cell growth and promotes cell apoptosis
Having established the metabolic effects of SAMC overexpression, we determined its influence on cell growth and proliferation. CaSki cells were transfected with pcDNA3-SAMC or empty vector for 24, 48 and 72 h, and then cell growth was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay. As shown in Fig. 5A , SAMC-overexpressing CaSki cells showed a significantly lower proliferation ability than control cells. Then we assessed at which phase of the cell cycle the growth was arrested by SAMC overexpression. The number of cells measured in each phase showed a more pronounced shift from the G1 to the S phase after 48 h in SAMC-overexpressing cells compared with control cells (Fig. 5B) , with a G1 to S phase ratio of 2.98 in control and 1.93 in SAMC-overexpressing cells. After 72 h a dramatic decrease of G1 cells and a drastic increase of S cells occurred (Fig. 5C ) resulting in a strong decrease in the G1/S ratio from 2.21 in control to 0.17 in SAMC-overexpressing cells. These results indicate that overexpression of the mitochondrial SAM carrier leads to cellular cycle arrest in the G1-S phase transition. Additionally, after 72 h of pcDNA3-SAMC transfection, the number of viable CaSki cells was reduced from 75.2% in control cells to 48.7% in SAMC-overexpressing cells (Fig. 5D) , whereas the percentage of apoptotic cells was increased from 24.8% (control cells) to 51.2% (SAMC-overexpressing CaSki cells) (upper panels of Fig. 5D,E) . Consistently, cytosolic release of cytochrome c, an indicator of the apoptotic process being executed, significantly increased in pcDNA3-SAMC compared with control CaSki cells (Fig. 5F ).
All together these data demonstrate that overexpression of SAMC has deleterious effects on cervical cancer cells growth and proliferation, suggesting that SLC25A26 could be a novel pro-apoptotic protein.
SLC25A26 overexpression increases the chemosensitivity for cisplatin
Finally, we checked whether SLC25A26 overexpression effectively sensitizes cells to a well-known chemotherapeutic agent frequently used for cervical cancer, cisplatin (cis-diaminodichloro platinum), which acts as an inducer of apoptosis [23] . A 24 h treatment with cisplatin significantly enhanced the apoptotic effect of SAMC overexpression at 72 h, as 93% of cells displayed the apoptotic marker annexin (Fig. 5D,E) . Cisplatin treatment alone induced apoptosis in 77% of the control cells, while cisplatin-free SAMC overexpression induced apoptosis in 51.2% of cells (Fig. 5D,E) indicating the additive and combined effect of the chemotherapeutic agent and the SAMC up-regulation on the apoptotic process. Interestingly, the cell cycle G1-S transition was much less evident at both 48 h (56.64%/17.56% = 3.22) and 72 h (48.47%/31.43% = 1.54) in cisplatin-treated compared with untreated pcDNA3-SAMC cells (Fig. 5B,C) .
All of these results indicate that SAMC overexpression enhances apoptotic sensitivity to cisplatin-induced cell death.
Discussion
Persistent infection with high-risk types of HPV is known to cause cervical cancer; however, additional genetic and epigenetic alterations are required for progression from a precancerous to invasive state [2] . Promoters of tumor suppressor genes involved in many cellular pathways are methylated in cervical precursors and invasive cancers [2] .
In the present study, we demonstrated for the first time that (a) the SLC25A26 gene is down-regulated in cervical cancer cells CaSki and HeLa by promoter hypermethylation; (b) its overexpression in CaSki cells has a strong impact on cell function by modifying mitochondrial epigenetics and rewiring methyl metabolism. This produces deleterious effects on cell growth and proliferation. Thus, epigenetic suppression of SLC25A26 might be part of the epigenetic reprogramming put in action in cervical cancer cells in order to take a selective advantage in survival and growth. Our data highlight also the importance of MeCP2, a global transcriptional repressor binding to methylated DNA and recruiting the SIN3A repressor complex to silence transcription via histone deacetylases [24] . In line with recent reports on the epigenetic role of MeCP2 in different cancers [19] , it is likely that MeCP2 is an epigenetic regulator rather than a transcriptional regulator.
In addition, the results presented in this work shed light on the role of methylation of mtDNA, which we not only detected with a very highly sensitive technique but also validated with respect to the D-loop fragment. mtDNA methylation appears to be strongly dependent on the amount of SAM entering the mitochondria. Intramitochondrial SAM levels over the physiological threshold trigger mtDNA hypermethylation, which leads to oxidative damage and cell injury through reduction or interruption of mitochondrial electron transport and ATP production (Fig. 6) . Intramitochondrial SAM is known to be important for ribosome assembly, but the inverse relationship between SAM levels and ND6 expression clearly excludes that the reduction of mitochondrial ATP synthesis, that we detect, is a consequence of impaired ribosome assembly. Furthermore, the observed changes in cells overexpressing SAMC are very unlikely to reflect a lower coenzyme Q synthesis, since higher intramitochondrial SAM levels, which we detect, should result in an increase rather that a decrease of coenzyme Q. Epigenetic modifications of the D-loop produce a specific reduction in the expression of mitochondrial genes, among which are the ND6 and ND2 subunits of the respiratory complex I and the Cytb protein, but not ND1. This differential expression is in line with previous work [25] , suggesting that (a) the epigenetic control of ND6, the key limiting peptide for the correct assembly of ND1 and ND2 [26] [27] [28] , acts as complex I activity modulator; and (b) the mechanism of mitochondrial epigenetic control is gene specific, as pointed out previously [25] . These findings clearly indicate that mitochondrial epigenetics, similarly to the well-established role of nuclear epigenetics, plays an important function in modulating cell life in physiological conditions and in pathological conditions such as cancer. It is noteworthy that, while mitochondrial ATP is significantly reduced by SAMC overexpression, cytosolic ATP remains substantially unchanged. This might indicate that cervical cancer cell bioenergetics is mainly oxidative rather than glycolytic, supporting the idea that not all tumor cell types are energetically dependent on glycolysis [29] . Indeed, bioenergetics of a given type of tumor can widely vary from glycolytic to oxidative depending on the oncogenes activated and the microenvironment [30] . Therefore, the mtDNA methylation profile could help in establishing the cancer cell's bioenergetic profile to improve pharmacological strategies interfering with distinctive steps of cancer energy production pathways [31] .
A recent work by Kishita and coworkers [32] describes three patients affected by a rare syndrome caused by recessive mutations of SLC25A26 that impair the transport function of SAMC, which is characterized by mitochondrial defects, including alterations of RNA stability, mitochondrial translation, biosynthesis of coenzyme Q, lipoic acid and ATP synthesis. It is worth noting that this study and ours are hardly comparable given that the two cellular models are very unlike, being from different pathological states. Furthermore, the two models cannot be superimposed since the SAMC-defective patients are characterized by 'loss of function' mutations, whereas SAMC-overexpressing CaSki cells describe a wild-type state with enhanced activity.
The new mutations in the D-loop region are probably related to the adverse conditions for cell survival at 72 h after SLC25A26 overexpression, among which oxidative stress and apoptosis are known to trigger the appearance of mtDNA mutations [33] . Interestingly, control CaSki cells show apparent CpG methylation at 48 h but not at 72 h. Although the reason for this finding is elusive, one explanation could be found in the nutrient deprivation of the culture medium at 72 h compared with 48 h, in line with a recent research highlighting the role of low nutrient availability in promoting a hypomethylated state [34] .
SAMC overexpression in CaSki cells produces deleterious effects, suggesting that SLCA25A26 could be a novel pro-apoptotic gene in these cancer cells. This unexpected role is based on two main cellular impairments, one dependent on hypermethylation of mtDNA and the other linked to the derangement of the methyl metabolism and decreased availability of GSH (Fig. 6 ). Increased uptake of SAM into mitochondria forces methionine to be converted to SAM. This causes homocysteine accumulation and GSH depletion (Fig. 6) . In fact, the increased mitochondrial SAM uptake is accompanied by a reduction of transsulfuration flux and accumulation of cytosolic homocysteine at the expenses of cysteine and glutathione. High homocysteine is a harmful metabolite, associated with abnormal gene expression and apoptosis [11, 35, 36] , and functionally relevant as an inducer of a shift from the G1 to the S phase in neurons [37] , similar to the G1-S transition arrest reported here after SAMC overexpression in CaSki cells. On the other hand, reduction of glutathione, the major non-enzymatic component of the intracellular antioxidant defense, is destined to increase oxidative damage, which is known to lead to a progressive cell transit into S phase, DNA damage and blockade of the cell cycle resulting in apoptosis [38] . Indeed, we found an increase of ROS production following SAMC overexpression, which could be a consequence of the redox dyshomeostasis and the failure of the antioxidant endogenous defense (Fig. 6) . It is known that ROS can be pro-tumorigenic, but also increase the susceptibility of cancer cells to death. Therefore, the amount of ROS produced by cancer cells must be maintained below the threshold that induces cell death [39] . Strong evidence links GSH levels, cancer growth and resistance. A direct correlation between GSH levels, proliferation and metastatic activity has been highlighted [21, 40, 41] . Up-regulation of GSH synthesis and GSH synthesizing enzymes has been noted in many cancer tissues [42] [43] [44] to the point that a higher GSH synthesizing potential in cancer cells is considered an adverse prognostic indicator [44] . GSH synthesis has also been indicated as a mechanism 
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The FEBS Journal 284 (2017) 967-984 ª 2017 Federation of European Biochemical Societies mediating cancer cells' resistance to cisplatin. Metabolic data point to a metabolic reprogramming of cancer cell metabolism toward GSH synthesis as a mechanism to increase cell survival and escape toxicity of chemotherapeutic agents [45] . Epigenetic down-regulation of SAMC gene could represent one of the events put in action by cancer cells to increase GSH synthesis (Fig. 6) . This hypothesis is supported by the levels of CBS expression, which progressively decrease as a consequence of SAMC up-regulation (Fig. 6) . In fact, CBS down-regulation might represent a compensatory mechanism that represses homocysteine to cystathionine conversion in an attempt to favor homocysteine channeling into SAM synthesis, required to support mitochondrial uptake, at the expenses of cysteine, and thus of GSH production. Furthermore, CBS is also sensitive to ROS attack [46] pointing to oxidative stress induced by SAMC overexpression as an additional mechanism exacerbating reduction of CBS enzymatic activity, leading to further homocysteine accumulation.
Another aspect of SAMC overexpression in CaSki cells concerns the sensitivity to cisplatin, a drug often used to treat advanced cervical cancer. The increased chemosensitivity to cisplatin could be related to the decreased level of glutathione (see above). Both pcDNA3-SAMC transfection and cisplatin treatment exert a combined effect on the apoptotic process [47] . The mechanisms by which SAMC and cisplatin are mutually reinforcing are not known. Since cisplatin is able to shift cancer cell metabolism from glycolysis to oxidative phosphorylation [48, 49] , it may be that the bioenergetic perturbation of oxidative phosphorylation, mediated by SAMC overexpression, could be the basis of the reinforcing apoptotic effect.
The results of our study demonstrate for the first time that increased SAM influx into mitochondria, due to SAMC overexpression, affects mtDNA methylation and mitochondrial function leading to impairment of oxidative phosphorylation, increased oxidative stress, decrease in GSH defense and apoptosis. Therefore, CaSki cervical cancer cells have an advantage in down-regulation of SLC25A26, which occurs through epigenetic hypermethylation of its promoter. These findings highlight that mitochondrial epigenetics might play an important role in cancer growth and progression. Thus, epigenetic modifications of mtDNA cannot be relegated to a secondary mechanism of regulation of transcription and protein synthesis in the organelles, representing a fundamental process able to influence the whole cell life in normal and pathological conditions including cancer.
Experimental procedures
Culture of CaSki cells and fractionation
CaSki cells (ATCC CRL-1550 TM , ATCC, Manassas, VA, USA) were grown in RPMI-1640 medium (ATCC TM , ATCC) with 10% fetal bovine serum (ATCC 30-2020 TM , ATCC), 2 mM L-glutamine and 1% penicillin/ streptomycin (cat. no. P4333, Sigma-Aldrich, St Louis, MO, USA) at 37°C in a humidified atmosphere with 5% CO 2 . For cell fractionation 2 9 10 7 cells of each sample were lysed within a Dounce tissue grinder (cat no. D8938, Sigma-Aldrich) in the presence of the lysis buffers provided by the Mitochondria Isolation Kit for Cultured Cells (cat. no. 89874, Thermo Fisher Scientific, Waltham, MA, USA); and the mitochondria were collected by differential centrifugation [25, 50] . Protein content was determined by using the Bradford protein assay (cat. no. 23236, Pierce/Thermo Fisher Scientific).
Treatments
Where indicated, CaSki cells were incubated with 20 lM cisplatin (a gift from F. Intini, University of Bari, Bari, Italy) for 24 h [51] or with 10 lM 5-Aza (cat. no. A2385, Sigma-Aldrich) up to 72 h [52] . The medium containing the drug or vehicle was replaced every 24 h during a 72-h period.
Construction of expression vector harboring SAMC complete coding sequence
One microgram of Human Testes Total RNA (cat. no. AM7972, Thermo Fisher Scientific) was reverse transcripted with GeneAmp RNA PCR core kit (cat. no. N8080143, Thermo Fisher Scientific) as described previously [53] . The full-length coding region of the human SLC25A26 (GenBank accession number NM_173471.3) was amplified from testes cDNA using the iProof High Fidelity DNA Polymerase (cat. no. 1725302, Bio-Rad, Hercules, CA, USA) and the primers listed in Table 1 in a final volume of 50 lL [54] . The PCR amplification product was purified using the High Pure PCR Product Purification Kit (cat. no. 11732668001, Roche Life Science, Indianapolis, IN, USA) and ligated with pcDNA3.1(+) vector (V790-20, Thermo Fisher Scientific) in the sense orientation. The fidelity of the human SLC25A26 insert in the pcDNA3.1(+) plasmid was verified by DNA sequencing using Big Dye Terminator Kit (cat. no. 4337455, Thermo Fisher Scientific).
Transient transfection
CaSki cells were transfected with the pcDNA3.1(+) vector containing the target SLC25A26 cDNA by FuGENE Ò HD Transfection Reagent (cat. no. E2311, Promega, Madison, WI, USA) as previously described [55] with some modifications. In brief, CaSki cells were plated 18-24 h prior to transfection, so that the monolayer cell density reached the optimal of~90% confluency at the time of transfection, in a T-150 flask (cat. no. CLS430825, Sigma-Aldrich) and grown in 47 mL of RPMI medium. 
Cell viability
Viability of CaSki cells transfected with pcDNA3-SAMC up to 72 h was evaluated as described previously [56] .
Flow cytometry analysis of the cell cycle
CaSki cells transfected with pcDNA3-SAMC and, where indicated, treated with cisplatin were harvested and washed twice with PBS. After fixing the cells in cold 70% ethanol at 4°C overnight, the cells were washed, resuspended in cold PBS and incubated with 10 mgÁmL À1 RNase (cat. no.
EN0531, Thermo Fisher Scientific) and 1 mgÁmL À1 propidium iodide (PI) (cat. no. P3566, Thermo Fisher Scientific) at 37°C for 30 min in the dark. The samples were analyzed by flow cytometry (BD Biosciences, San Diego, CA, USA), and the percentage of cells in the G0/G1, S and G2/M phases was determined using Cell Quest acquisition software (BD Biosciences) as described [57] .
Annexin V-FITC flow cytometric analysis for apoptotic cell death
CaSki cells transfected with pcDNA3-SAMC and, where indicated, treated with cisplatin were harvested, washed twice with ice-cold PBS and resuspended at a density of 1 9 10 6 cellsÁmL À1 in 100 lL of binding buffer containing 5 lL of annexin V/FITC (cat. no. A13199, Thermo Fisher Scientific). After incubation at room temperature for 15 min in the dark, 400 lL of binding buffer was added to each sample. Apoptosis was analyzed by flow cytometry (BD Biosciences) for at least 10 000 events as described [57] .
Bisulfite treatment
Bisulfite conversion of 300 ng of genomic DNA or purified mtDNA was performed by using the EZ DNA Methylation-Direct Kit (cat. no. D5021, Zymo Research, Irvine, CA, USA) according to the manufacturer's protocol. To ensure that cytosine conversion was complete, alternative bisulfite modifications were performed by using the EZ DNA Methylation-Gold Kit (cat. no. D5006, Zymo Research) and the Cells-to-CpG TM Bisulfite Conversion Kit (cat. no. 4445554, Thermo Fisher Scientific) according to the manufacturer's protocol. The effectiveness of the entire experimental procedure was also evaluated by analyzing CpGenome TM Universal Unmethylated DNA (cat. no. S7821, Sigma-Aldrich). For each procedure of bisulfite treatment, unconverted primers randomly covering the entire mtDNA molecule, including those used for the Dloop analysis, were used in polymerase chain reactions (PCR), as negative controls [18] .
ROS detection
For intracellular ROS analysis, CaSki cells transfected with pcDNA3-SAMC for 48 and 72 h were incubated with 10 lM 2 0 ,7 0 -dichlorodihydrofluorescein diacetate (cat. no. D399, Thermo Fisher Scientific) for 30 min [58] . For extracellular ROS analysis, CaSki cells transfected as described above in RPMI-modified medium without phenol red (cat. no. R8755, Sigma-Aldrich) were treated with 0.2 mM lucigenin (Alexis, Loerrach, Germany) [59] . The fluorescence and the chemiluminescence resulting from ROS were analyzed using a microplate reader (Victor X3; Perkin Elmer, Waltham, MA, USA). [63, 64] . The best fit was determined using regression analysis of the peak analyte area.
Real-time PCR
Total RNA was extracted from 1 9 10 6 CaSki and HeLa (ATCC CCL2 TM , ATCC) cells by GenElute Mammalian Total RNA Miniprep Kit (cat. no. RTN70, Sigma-Aldrich) and transcribed by reverse transcriptase. Cervix cDNAs were prepared by reverse transcription of total RNA from Human Cervix (cat. no. AM6992, Thermo Fisher Scientific). Then real-time PCR was carried out as reported [65] . Assay-ondemand for human SAMC (cat. no. Hs00384779_m1) and human b-actin (cat. no. Hs99999903_m1) were purchased from Thermo Fisher Scientific. The transcript levels were normalized against the expression levels of b-actin.
Isolation of nuclear and purified mitochondrial DNA
Genomic DNA was isolated with the GenElute Mammalian Genomic DNA Miniprep Kit (cat. no. G1N350, SigmaAldrich). Purified mitochondria (see 'Culture of CaSki cells and fractionation') were pre-treated with DNase I (cat. no. AM2222, Thermo Fisher Scientific) in 3 lL incubation buffer (109, 400 mM Tris/HCl, 100 mM NaCl, 60 mM MgCl 2 , 10 mM CaCl 2 ; pH 7.9) for 3 h at 37°C to avoid nuclear DNA contamination. Then mtDNA was isolated with mtDNA Isolation Kit (K280-50, BioVision, Milpitas, CA, USA). mtDNA concentration and purity were determined by electrophoresis on a 0.7% agarose gel and by measuring A 260 and A 280 and calculating the A 260 /A 280 ratio [15, 66] . To further rule out contamination with nuclear DNA, PCRs were performed to detect two specific nuclear DNA regions (human beta-globin and SLC25A26 gene promoter) and one from the mitochondrial genome (ND6) [67] using the primers listed in Table 1 7246, Clontech). The relative mtDNA copy number was defined as the total amount of mtDNA divided by the total amount of nuclear DNA.
Quantification of mtDNA methylation
Mitochondrial DNA (about 2 lg) was digested by nuclease S1 (cat. no. EN0321, Thermo Fisher Scientific), phosphodiesterase I (cat. no. P3243, Sigma-Aldrich) and alkaline phosphatase (APMB-RO, Roche Life Science) [15, 68] . For mass spectrometry analysis of 5-methyl-2 0 -deoxycytidine (mdC) and 2 0 -deoxycytidine (dC), using 2 0 -deoxyguanosine (dG) as internal standard [15] , the following multiple reaction monitoring transitions were identified as follows: m/z 242.10 > 126.10 for mdC, m/z 228.10 > 112.10 for dC and m/z 268.1 > 152.3 for dG [15] . Calibration curves were established using standards, processed under the same conditions as the samples, at five concentrations [63, 64, 69] . The best fit was determined using regression analysis of the peak analyte area.
Chromatin immunoprecipitation
ChIP experiments were performed as previously reported [58] . Briefly, 2 9 10 7 CaSki cells exposed up to 72 h to 10 lM 5-Aza were fixed by 1% formaldehyde at 37°C for 10 min; afterwards, the cells were lysed and sheared by sonication in a 1% SDS lysis buffer to generate cellular chromatin fragments of 400-500 bp. The chromatin was immunoprecipitated for 14-16 h at 4°C using a specific antibody to MeCP2 (cat. no. SAB4800012, Sigma-Aldrich).
After reverse cross-linking, chromatin immunoprecipitates were purified and 2 lL of each sample was analyzed by PCR using the primers listed in Table 1 , suitable to amplify the À302 to À7 bp region of the SLC25A26 gene promoter.
Bisulfite sequencing
For DNA methylation analysis, bisulfite-modified DNA was amplified with specific primers using TaKaRa EpiTaq TM HS (cat. no. R110A, Clontech). Mitochondrial DNA was amplified at the D-loop using the primers listed in Table 1 . The À370 to +1 bp region of the SLC25A26 gene promoter was amplified using the primers listed in Table 1 . PCR was run under the following conditions: preincubation at 98°C for 10 s, run for 40 cycles at 98°C for 10 s, 55°C for 30 s, and 72°C for 30 s, extension at 72°C for 5 min. The PCR products, purified by High Pure PCR Product Purification Kit (cat. no. 11732668001, Roche Life Science), were cloned into pCR4-TOPOÒ Vector (cat. no. K457502, Thermo Fisher Scientific) according to the manufacturer's protocol. Fifteen positive clones per sample were analyzed. Plasmids were purified using PureLink Quick Plasmid Miniprep Kit (cat. no. K457502, Thermo Fisher Scientific) and analyzed by automated sequencing in an ABI PRISM 310 (Thermo Fisher Scientific) with the Big Dye Terminator Cycle Sequencing Ready Reaction Kit (cat. no. 4337455, Thermo Fisher Scientific).
Primer design for PCR reactions
For DNA methylation analysis primers were designed using METHPRIMER Software (http://www.urogene.org/methprimer/ index1.html). Some precautions were taken for primer design: (a) cytosines within CpG sites were avoided; (b) where possible, DNA regions characterized by low polymorphism content were preferred; (c) a short size of the amplicons was defined (range: 350-550 bp); (d) generally 26-32 bases are required; (e) annealing temperatures of 55-60°C were preferred.
Other methods
For western blotting analysis, proteins were electroblotted onto nitrocellulose membranes (cat. no. 1620112, Bio-Rad), and subsequently treated with the following antibodies: rabbit polyclonal anti-cytochrome P450 reductase (cat. no. ab13513, Abcam) at 1 : 1000; mouse monoclonal anti-actin (cat. no. MAB1501, Sigma-Aldrich) at 1 : 1000; mouse monoclonal anti-porin (cat. no. ab14734, Abcam) at 1 : 3000; rabbit polyclonal anti-lamin (cat. no. ab26300, Abcam) at 1 : 500; mouse monoclonal anti-catalase (cat. no. C0979, Sigma-Aldrich) at 1 : 2000; rabbit anti-cyclophilinD (cat. no. GTX79245, Genetex, Irvine, CA, USA) at 1 : 3000; anti-SAMC (cat. no. ab 182103, Abcam) at 1 : 500; rabbit anti-ND6 (cat. no. sc-20510-R, Santa Cruz Biotechnology, Dallas, TX, USA) at 1 : 500; rabbit polyclonal anti-ND2 (cat. no. PA5-37185, Thermo Fisher Scientific) at 1 : 500; rabbit polyclonal anti-ND1 (cat. no. PA5-36493, Thermo Fisher Scientific) at 1 : 500; rabbit polyclonal anti-Cytb (PA5-26626, Thermo Fisher Scientific) at 1 : 500; mouse anti-cytochrome c (cat. no. sc-13560, Santa Cruz Biotechnology) and mouse monoclonal anti-b-actin (cat. no. sc-47778, Santa Cruz Biotechnology). The immunoreactions were detected by the SuperSignal TM West Pico Chemiluminescent Substrate (cat. no. 34080, Thermo Fisher Scientific).
Statistical analysis
Statistical significance of differences was determined using one-way ANOVA. Data are expressed as means AE standard deviation and differences were considered as significant (*P < 0.05); very significant (**P < 0.01) and highly significant (***P < 0.001).
